Dry Age-Related Macular Degeneration Pipeline constitutes 70+ key companies continuously working towards developing 80+ Dry Age-Related Macular Degeneration treatment therapies, analyzes DelveInsight.
Dry Age-Related Macular Degeneration Overview:
Age-related macular degeneration (AMD) is a progressive eye disorder that damages the macula, the central part of the retina, resulting in the gradual loss of central vision. It mainly affects individuals over the age of 50 and is a major cause of irreversible vision loss in older adults, particularly in developed countries. First identified over 80 years ago, AMD now affects approximately 170 million people globally, making it the third leading cause of vision impairment worldwide. The disease exists in two forms: dry AMD, which progresses slowly, and wet AMD, which can cause rapid and severe vision loss. Early stages are often symptomless, though signs like drusen (yellow deposits) may be detected during eye exams. In intermediate or advanced stages, patients may experience blurred central vision, dark spots, or difficulty adapting to changes in lighting.
Clinicians use advanced imaging techniques such as fundus photography, fluorescein angiography (FAF), infrared (IR) reflectance, and especially optical coherence tomography (OCT) to diagnose and monitor AMD. Over the past 20 years, spectral-domain OCT (SD-OCT) has become the gold standard for visualizing retinal layers, tracking drusen, geographic atrophy, and other structural changes. Emerging tools like polarization-sensitive OCT (PS-OCT) may further enhance imaging and diagnosis in both research and clinical settings.
Currently, there are no approved treatments for dry AMD. Management focuses on regular monitoring to track progression and intervene early if necessary. Research is actively exploring various therapeutic strategies, including lifestyle modifications, AREDS-based nutritional supplements, anti-inflammatory and anti-toxic agents, visual cycle modulators, complement inhibitors, gene therapy, and cell-based treatments, all aimed at preventing progression or restoring lost vision.
Request for a detailed insights report on Dry Age-Related Macular Degeneration pipeline insights
“Dry Age-Related Macular Degeneration Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Dry Age-Related Macular Degeneration Therapeutics Market.
Key Takeaways from the Dry Age-Related Macular Degeneration Pipeline Report
-
DelveInsight’s Dry Age-Related Macular Degeneration pipeline report depicts a robust space with 70+ active players working to develop 80+ pipeline therapies for Dry Age-Related Macular Degeneration treatment.
-
In June 2024, Stealth BioTherapeutics enrolled the first participant in the Phase III ReNEW clinical trial, which is part of a larger program to evaluate elamipretide as a treatment for dry age-related macular degeneration (AMD). This randomized, double-blind, placebo-controlled study will examine the efficacy, safety, and pharmacokinetics of daily subcutaneous injections of elamipretide.
-
Key Dry Age-Related Macular Degeneration companies such as Belite Bio, Inflammx Therapeutics, Ocugen, OliX Pharmaceuticals, Gensight Biologics, Alkeus Pharmaceuticals, Dobecure, Cognition Therapeutics, Aviceda Therapeutics, Galimedix Therapeutics, Mitotech, Annexon, Inc., NGM Biopharmaceuticals, Johnson & Johnson, Lineage Cell Therapeutics, Astellas Pharma, Regenerative Patch Technologies, Hoffmann-La Roche, Boehringer Ingelheim, ONL Therapeutics, and others are evaluating new drugs for Dry Age-Related Macular Degeneration to improve the treatment landscape.
-
Promising Dry Age-Related Macular Degeneration pipeline therapies in various stages of development include Tinlarebant (LBS-008), XIFLAM, OCU410, OLX301A, GS030, and others.
Dry Age-Related Macular Degeneration Pipeline Analysis
The report provides insights into:
-
The report provides detailed insights into the key companies that are developing therapies in the Dry Age-Related Macular Degeneration Market.
-
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Dry Age-Related Macular Degeneration treatment.
-
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Dry Age-Related Macular Degeneration market.
Download our free sample page report on Dry Age-Related Macular Degeneration pipeline insights
Dry Age-Related Macular Degeneration Emerging Drugs
-
Tinlarebant (LBS-008): Belite Bio
-
XIFLAM: Inflammx Therapeutics
-
OCU410: Ocugen
-
OLX301A: OliX Pharmaceuticals
-
GS030: Gensight Biologics
Dry Age-Related Macular Degeneration Companies
Over 70 leading companies are actively working on therapies for Dry Age-related Macular Degeneration (Dry-AMD). Among them, Belite Bio has drug candidates that have progressed to the advanced Phase III stage of development.
DelveInsight’s report covers around 80+ products under different phases of clinical development like
-
Late stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I) along with the details of
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
Dry Age-Related Macular Degeneration pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
-
Intravenous
-
Subcutaneous
-
Oral
-
Intramuscular
Dry Age-Related Macular Degeneration Products have been categorized under various Molecule types such as
-
Monoclonal antibody
-
Small molecule
-
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Dry Age-Related Macular Degeneration Therapies and Key Companies: Dry Age-Related Macular Degeneration Clinical Trials and advancements
Dry Age-Related Macular Degeneration Pipeline Therapeutic Assessment
• Dry Age-Related Macular Degeneration Assessment by Product Type
• Dry Age-Related Macular Degeneration By Stage
• Dry Age-Related Macular Degeneration Assessment by Route of Administration
• Dry Age-Related Macular Degeneration Assessment by Molecule Type
Download Dry Age-Related Macular Degeneration Sample report to know in detail about the Dry Age-Related Macular Degeneration treatment market @ Dry Age-Related Macular Degeneration Therapeutic Assessment
Table of Content
1. Report Introduction
2. Executive Summary
3. Dry Age-Related Macular Degeneration Current Treatment Patterns
4. Dry Age-Related Macular Degeneration – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Dry Age-Related Macular Degeneration Late-Stage Products (Phase-III)
7. Dry Age-Related Macular Degeneration Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Dry Age-Related Macular Degeneration Discontinued Products
13. Dry Age-Related Macular Degeneration Product Profiles
14. Dry Age-Related Macular Degeneration Key Companies
15. Dry Age-Related Macular Degeneration Key Products
16. Dormant and Discontinued Products
17. Dry Age-Related Macular Degeneration Unmet Needs
18. Dry Age-Related Macular Degeneration Future Perspectives
19. Dry Age-Related Macular Degeneration Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Dry Age-Related Macular Degeneration Pipeline Reports Offerings
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/